Patients with lower systolic blood pressure (SBP) may obtain greater absolute benefits from treatment with the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan when compared to patients with a higher SBP according to a study published in European Heart Journal. However, these greater benefits may come at the expense of more hypotension-related adverse events. Read more >>>